Market revenue in 2022 | USD 165.5 million |
Market revenue in 2030 | USD 1,050.2 million |
Growth rate | 26% (CAGR from 2022 to 2030) |
Largest segment | Cell therapy |
Fastest growing segment | Gene Therapy |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Gene Therapy, Cell Therapy |
Key market players worldwide | Lonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy manufacturing market will help companies and investors design strategic landscapes.
Cell therapy was the largest segment with a revenue share of 67.92% in 2022. Horizon Databook has segmented the Australia cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
With rising development efforts in Australia, the market is likely to witness increased demand for cell and gene therapies. For instance, in January 2022, the NSW government announced leveraging cell and gene therapy expertise to establish a commercial-scale viral vector manufacturing facility in the country.
Similarly, in May 2019, Therapeutic Innovation Australia (TIA) invested USD 8.8 million in cell and gene therapy facilities across Australia. Numerous clinical studies in cell and gene therapies are ongoing or have already been completed in the country, which has the potential to transform the treatment of various diseases, including cancer.
Moreover, announcements regarding reimbursement for Kymriah CAR-T therapy for acute lymphoblastic leukemia further emphasize the promising therapeutic potential of cell and gene therapies.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia cell and gene therapy manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Australia cell and gene therapy manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account